骨髓纤维化:在鲁克索利提尼布失效后的治疗选择
Ruth Stuckey1, Adrián Segura Díaz1, María Teresa Gómez-Casares1,2
1Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.
Current oncology (Toronto, Ont.)
|June 25, 2025
概括
异构干细胞移植可以治愈髓纤维化,但它是有限的. 像ruxolitinib这样的JAK抑制剂可以控制症状,但不能改善存活率,这导致了对新疗法的研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 全基性造血干细胞移植是治疗髓纤维化 (MF) 的唯一方法,但其使用受到高风险和患者资格的限制.
- 鲁克索利提尼布是中等和高风险的MF的标准一线治疗,提供症状缓解和缩,但没有生存益处.
- 卢克索利提尼布的使用可能受到毒性和未能预防疾病进展的限制,这构成了临床挑战.
研究的目的:
- 审查目前用于骨髓纤维化治疗的JAK抑制剂疗法.
- 讨论新的药物和治疗策略,用于抗鲁克索利提尼布或耐火性MF.
- 突出治疗顺序和下一代顺序对改善患者治疗结果的重要性.
主要方法:
- 在骨髓纤维化治疗中对JAK抑制剂和新药的文献综述.
- 对鲁克索利提尼布耐药患者当前治疗选择的分析.
- 讨论新兴的向疗法和组合策略.
主要成果:
- 批准费德拉提尼布,帕克里蒂尼布和莫梅洛提尼布扩大了治疗选择,特别是在细胞衰竭患者中.
- 许多向药物正在临床试验中,为骨髓纤维化管理提供了新的希望.
- 优化治疗顺序和纳入先进的诊断是改善患者结果的关键.
结论:
- 虽然JAK抑制剂提供了好处,但在管理ruxolitinib失败和疾病进展方面仍然存在挑战.
- 新型药物和个性化治疗策略的开发对于推进骨髓纤维化治疗至关重要.
- 将下一代测序纳入治疗决策将对改善多发性纤维患者的生存率和生活质量至关重要.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34


